131 related articles for article (PubMed ID: 37260052)
21. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
22. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.
Riazi-Esfahani H; Masoomian B; Khodabandeh A; Amini A; Taghizadeh S; Boujabadi L; Sharifkashani S; Shields CL; Ghassemi F
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1167-1175. PubMed ID: 36401651
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal injection of melphalan in the treatment of retinoblastoma with vitreous cavity seeding.
Sun YB; Hui P; Punyara K; Bi MC; Li SH; Teng SY; Song E
Chin Med J (Engl); 2013; 126(8):1587. PubMed ID: 23595400
[No Abstract] [Full Text] [Related]
25. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.
Francis JH; Abramson DH; Gobin YP; Marr BP; Tendler I; Brodie SE; Dunkel IJ
Ophthalmology; 2015 May; 122(5):1016-22. PubMed ID: 25616769
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
27. Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.
De Francesco S; Galluzzi P; Bracco S; Menicacci F; Motolese E; Hadjistilianou T
Int Ophthalmol; 2015 Dec; 35(6):887-95. PubMed ID: 26416040
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
29. Eye-preservation treatment of retinoblastoma with vitreous seeding.
Kaneko A; Suzuki S
Jpn J Clin Oncol; 2003 Dec; 33(12):601-7. PubMed ID: 14769836
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma.
Abramson DH; Catalanotti F; Brodie SE; Kellick MG; Francis JH
Ophthalmic Genet; 2018 Jun; 39(3):353-356. PubMed ID: 29513055
[TBL] [Abstract][Full Text] [Related]
31. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma.
Francis JH; Marr BP; Brodie SE; Gobin YP; Abramson DH
JAMA Ophthalmol; 2014 Aug; 132(8):1024-5. PubMed ID: 25124953
[No Abstract] [Full Text] [Related]
32. Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.
Karl MD; Francis JH; Iyer S; Marr B; Abramson DH
J Pediatr Ophthalmol Strabismus; 2017 May; 54(3):185-190. PubMed ID: 28092395
[TBL] [Abstract][Full Text] [Related]
33. Intra-Arterial Chemotherapy for Retinoblastoma: A Single-Center Experience.
Akyüz C; Kıratlı H; Şen H; Aydın B; Tarlan B; Varan A
Ophthalmologica; 2015; 234(4):227-32. PubMed ID: 26368674
[TBL] [Abstract][Full Text] [Related]
34. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.
Munier FL; Soliman S; Moulin AP; Gaillard MC; Balmer A; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1084-7. PubMed ID: 22368262
[TBL] [Abstract][Full Text] [Related]
35. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
Brodie SE; Munier FL; Francis JH; Marr B; Gobin YP; Abramson DH
Doc Ophthalmol; 2013 Feb; 126(1):79-84. PubMed ID: 23143758
[TBL] [Abstract][Full Text] [Related]
36. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
[No Abstract] [Full Text] [Related]
37. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.
Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH
Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243
[TBL] [Abstract][Full Text] [Related]
38. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.
Berry JL; Shah S; Bechtold M; Zolfaghari E; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28646513
[TBL] [Abstract][Full Text] [Related]
40. Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review.
Ong SJ; Chao AN; Wong HF; Liou KL; Kao LY
Jpn J Ophthalmol; 2015 Mar; 59(2):109-17. PubMed ID: 25465196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]